Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | EEF2K | O00418 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886441 | 0.91 | ATM (0.34) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL28307697 | 0.89 | ATM (0.33) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL30770698 | 0.85 | STAT3 (0.39) | STAT3EEF2KPLK1PLK2 | |
| SCHEMBL14138100 | 0.83 | NPC1 (0.31) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL11247339 | 0.81 | STAT3 (0.39) | STAT3EEF2KPLK1PLK2NPC1 | |
| SCHEMBL8611116 | 0.79 | XIAP (0.37) | MAPK1 | |
| SCHEMBL8613270 | 0.74 | ACHE (0.37) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL8926934 | 0.73 | CNR1 (0.33) | LMNAATM | |
| P-Xyloquinone SCHEMBL49964 | 0.72 | PLK1 (0.60) | STAT3EEF2KPLK1PLK2NPC1 | |
| SCHEMBL14138085 | 0.72 | MAPT (0.33) | NPC1LMNAMAPK1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024003428-A1 | QUINONE-DERIVED COMPOUNDS AND USE THEREOF AGAINST LEISHMANIA SPP | UNIVERSIDAD DE LA LAGUNA (ES) | 2024-01-04 | — | — | WO | claimed |
| US-20260022089-A1 | QUINONE-DERIVED COMPOUNDS AND USE THEREOF AGAINST LEISHMANIA SPP | UNIVERSIDAD DE LA LAGUNA (ES) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022089-A1 | QUINONE-DERIVED COMPOUNDS AND USE THEREOF AGAINST LEISHMANIA SPP | G6PD, SDHA, DHPS | STAT3 4537/4885EEF2K 2707/4885PLK1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.